January 29, 2010 (FinancialWire) — Pharmasset, Inc. (NASDAQ: VRUS) announced TODAY the pricing of an underwritten offering of 1.6 million shares of its common stock at a price of $18.75.

The company said it expects to receive net proceeds of around $28.6 million. In addition, Pharmasset has granted the underwriter a 30-day option to purchase up to an additional 230,400 shares of its common stock. The offering is scheduled to close on February 2, 2010.

New Jersey-based Pharmasset is a clinical-stage pharmaceutical company focused on discovering, developing and commercializing novel drugs to treat viral infections.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.